Pipeline updates are highly awaited events in the
pharma/biotech sector as they play an important role in deciding
whether or not to invest in a particular company. These updates
provide information on experimental drugs and at times give an
insight into the commercial potential of the candidate once it is
successfully developed and commercialized.
With the commencement of 2014, several companies have been
providing an update on their pipelines candidates and their
future developmental plans. Earlier this week,
) provided an update on its pipeline including the U.S. Food and
Drug Administration's (FDA) feedback on XP23289 and its
commercialization plans for Horizant.
ACTELION LTD (ALIOF): Get Free Report
CORONADO BIOSCI (CNDO): Free Stock Analysis
ACCELERON PHARM (XLRN): Free Stock Analysis
XENOPORT INC (XNPT): Free Stock Analysis
To read this article on Zacks.com click here.
XP23289 is being developed for the treatment of relapsing forms
of multiple sclerosis (MS). XenoPort received a feedback from the
FDA on XP23289. The FDA said that XenoPort should explore
different doses of XP23829 to evaluate the potential advantages
of doses that produced either higher or lower monomethyl fumarate
(MMF) exposure. XenoPort intends to continue discussions with the
agency regarding the regulatory pathway for the candidate.
Meanwhile, XenoPort will also file an Investigational New Drug
(IND) application for XP23829 for the treatment of
moderate-to-severe plaque psoriasis. A phase II study for this
indication could commence by mid 2014.
As far as the performance of Horizant is concerned, since
XenoPort started promoting the drug (Jun 2013), the company said
that it expects the Horizant to break-even and turn profitable by
the end of 2015.
With Horizant being a lead product in XenoPort's portfolio,
results from the post-marketing study on the drug will be game
changing for the company. We expect investor focus to remain on
XenoPort carries a Zacks Rank #3 (Hold). Some better ranked
stocks in the same sector include
Coronado Biosciences, Inc.
Acceleron Pharma, Inc.
). While Actelion and Coronado Biosciences are Zacks Rank #1
(Strong Buy) stocks, Acceleron is a Zacks Rank #2 (Buy)